Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.

Service

Funding, debt advisory & ECM

Parties

Talk to the deal team

Geoff Nash

Partner

London, United Kingdom
Oaklins Cavendish

View profile Get in touch

Related deals

SulAmérica and Rede D’Or São Luiz have announced a combination

Financial Services | Healthcare

SulAmérica and Rede D’Or São Luiz have announced a combination

SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.

Learn more

Agar Scientific has been acquired by Calibre Scientific

Private Equity | Healthcare

Agar Scientific has been acquired by Calibre Scientific

Agar Scientific Ltd. (Agar) has been sold to Molecular Dimensions Limited, a subsidiary of Calibre Scientific, Inc., a US-based life sciences company, owned by international private investment firm StoneCalibre.

Learn more

Frenkel Topping has completed the placing of new shares

Financial Services

Frenkel Topping has completed the placing of new shares

Frenkel Topping has raised funds to continue consolidating the highly fragmented professional services marketplace in this niche sector.

Learn more